KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2025)

Vir Biotechnology's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.3 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 60.53% to -$0.3 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.15, a 17.54% increase, with the full-year FY2025 number at -$3.16, up 17.49% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.3 in Q4 2025 for Vir Biotechnology, up from -$1.17 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for VIR hit a ceiling of $3.94 in Q4 2021 and a floor of -$1.56 in Q3 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.19 across 5 years, with a median of -$0.78 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 563.53% in 2021 and later crashed 226.09% in 2022.
  • Tracing VIR's EPS (Weighted Average and Diluted) over 5 years: stood at $3.94 in 2021, then crashed by 119.04% to -$0.75 in 2022, then dropped by 14.67% to -$0.86 in 2023, then rose by 11.63% to -$0.76 in 2024, then soared by 60.53% to -$0.3 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VIR at -$0.3 in Q4 2025, -$1.17 in Q3 2025, and -$0.8 in Q2 2025.